Advanced search

Novel therapeutic modalities in pediatric inflammatory bowel disease.

Michael Wilschanski, Eyal Shteyer

Journal: The Israel Medical Association journal : IMAJ 2009;10(11):816-20

PMID: 19070296

Free Full Text on Israel Medical Association View on PubMed

Abstract

Management of inflammatory bowel disease in childhood poses great challenges. Apart from the disease complications, the drugs' adverse affects, especially corticosteroids, are significant. In the past decade major progress was made in elucidating the pathogenesis of IBD, which led to new treatment options aiming to achieve better control of the disease and decrease the various complications of current therapy. In this review we provide an overview of novel therapies for IBD, their efficacy, safety and their current use in children.

Address: Pediatric Gastroenterology Unit, Hadassah-Hebrew University Hospitals, Jerusalem, Israel. [email protected]

Link outs

Free resources

Full Text Sources:

Medical:

Other Literature Sources:

Miscellaneous:

MeSH Terms: Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Basiliximab, Child, Crohn Disease, Enzyme Inhibitors, Granulocyte-Macrophage Colony-Stimulating Factor, Humans, Immunosuppressive Agents, Inflammatory Bowel Diseases, Integrin alpha4, Mycophenolic Acid, Natalizumab, Probiotics, Receptors, Interleukin-6, Recombinant Fusion Proteins, Tacrolimus, Treatment Outcome
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

Sponsor Sponsor Sponsor Sponsor Sponsor Sponsor Sponsor

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.